Pharmaust Limited (NUZ) AI Stock Analysis

Neurizon Therapeutics has requested and received a trading halt in its shares on the ASX, effective from the open of trading on 29 October 2026. The halt is expected to remain in place until either normal trading resumes on Monday, 2 November 2026, o...

Neurizon completed enrolment of 250 participants in Regimen I of the Phase 2/3 HEALEY ALS Platform Trial at 78 U.S. sites, accelerating the expected topline data to late Q2 2027 and maintaining statistical power without increasing funding needs. The...

Neurizon Therapeutics has called its Annual General Meeting for 25 November 2026 at 2.00pm AEDT, to be conducted as a hybrid event at legal firm Gilbert + Tobin’s Melbourne offices and via an online video-conferencing facility. The company has...

Neurizon Therapeutics has rescheduled its 2026 Annual General Meeting to 25 November 2026 in Melbourne, with further details to be issued in a forthcoming Notice of Meeting. The board has signalled its intention to use the AGM as a forum to engage di...

Neurizon Therapeutics Limited has announced the cessation of a tranche of equity-linked securities following the lapse of conditional rights. A total of 4,256,000 options expiring in June 2032 and 1,140,000 performance rights have lapsed after their...

Neurizon Therapeutics has released an updated investor presentation outlining its strategy as it progresses lead asset NUZ-001 through late-stage clinical development, including a 250-participant Phase 2/3 HEALEY ALS Platform Trial with topline data...

Neurizon Therapeutics has received written feedback from the U.S. Food and Drug Administration indicating that positive Phase 2/3 results from the HEALEY ALS Platform Trial of its lead ALS candidate NUZ-001 could support a traditional approval pathwa...

Neurizon Therapeutics has disclosed a change in director Sergio Duchini’s holdings, reflecting an on-market purchase of additional fully paid ordinary shares. The transaction underscores ongoing insider investment in the company and may be view...

Neurizon Therapeutics Limited has announced the cessation of 1,000,000 NUZAA convertible notes following their repayment or redemption without conversion on 14 September 2026. The move reduces outstanding convertible debt and may simplify the company...

Neurizon Therapeutics will redeem 1,000,000 convertible notes held by Obsidian for total consideration of US$1,150,000, cutting the outstanding notes to 750,000 and securing a two-month agreement that Obsidian will not sell Neurizon shares. The board...

Neurizon Therapeutics Limited has applied for quotation of 7,436,765 new ordinary fully paid shares on the ASX, to be issued on September 10, 2026. The application, lodged as an Appendix 2A, reflects additional securities resulting from the exercise...

Neurizon Therapeutics has secured participation in a multimillion-dollar, multi-year NIH-funded Expanded Access Protocol that will allow up to 200 people in the U.S. living with ALS, who are ineligible for clinical trials, to receive its lead investi...

Neurizon Therapeutics has appointed Dr Chris Bremer as Chief Executive Officer, effective 1 October 2026, as the company advances its lead ALS candidate NUZ-001 through a registrational Phase 2/3 trial. Bremer will initially serve as CEO without join...

Neurizon Therapeutics Limited has applied for quotation on the ASX of 9,116,092 ordinary fully paid shares under the code NUZ.The new securities, issued on August 26, 2026, arise from the exercise or conversion of existing options or other convertibl...

Neurizon Therapeutics Limited has lodged its corporate governance statement and completed Appendix 4G for the financial year ended 30 June 2026, confirming compliance with ASX Listing Rules. The statement, approved by the board as at 25 August 2026,...

Neurizon Therapeutics Limited has reported a sharply improved financial position for the year ended 30 June 2026, despite remaining loss-making. Other income surged by 844.2% to $17.77 million, helping cut the after-tax loss attributable to owners by...

Neurizon Therapeutics Limited has notified the market of the issuance of a substantial tranche of unquoted equity securities under its employee incentive scheme. The company will issue more than 14 million performance rights and approximately 8 milli...

Neurizon Therapeutics has appointed Dr. Steve Nanchen, Senior Advisor for External Innovation at Elanco Animal Health, as a non-voting Board Observer, reinforcing the strategic ties between the two companies. The move follows Neurizon’s exclusi...

Neurizon reported a strong June quarter marked by rapid clinical progress in its NUZ‑001 program within the Phase 2/3 HEALEY ALS Platform Trial, expanding Regimen I from 160 to 250 participants while maintaining statistical power and funding re...